All In Biotech

Drug Trial Radar · NCT02737501

ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants

A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer

Last checked: Nov 19, 2026Latest source record: Aug 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 275 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

275

Actual

Start

May 26, 2016

Primary completion

Jul 28, 2020

Study completion Jan 29, 2021

Sponsor

Lead sponsor
Ariad PharmaceuticalsTakeda (TAK)
Sponsor type
Industry
First posted
Apr 14, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to compare the efficacy of brigatinib to that of crizotinib in ALK+ locally advanced or metastatic non-small cell lung cancer (NSCLC) participants naive to ALK inhibitors, as evidenced by progression-free survival (PFS).

Conditions

  • Non-small Cell Lung Cancer
  • Lung Cancer
  • Advanced Malignancies
  • Carcinoma

Interventions

  • BrigatinibDrug

    Brigatinib tablets

  • CrizotinibDrug

    Crizotinib tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS)Time frame: Up to end of study (Up to 56 months)

Locations

91 sites in 19 countries. Site status is shown where the registry gives one.

  • USOR - Arizona Oncology Associates - Sedona

    Sedona, Arizona

  • Kaiser Permanente Bellflower Medical Offices

    Bellflower, California

  • University of Colorado Cancer Center

    Aurora, Colorado

  • Rocky Mountain Cancer Centers - Boulder

    Boulder, Colorado

  • Sylvester Comprehensive Cancer Center

    Deerfield Beach, Florida

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • West Michigan Cancer Center

    Kalamazoo, Michigan

  • Minnesota Oncology

    Coon Rapids, Minnesota

  • Montefiore Medical Center

    The Bronx, New York

  • Oncology Hematology Care - Blue Ash

    Cincinnati, Ohio

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma

  • Virginia Cancer Specialists - Fairfax Office

    Fairfax, Virginia

  • Saint George Hospital

    Kogarah, New South Wales, Australia

  • Royal North Shore Hospital

    St Leonards, New South Wales, Australia

  • Monash Medical Centre

    Bentleigh East, Victoria, Australia

  • Saint Vincent's Hospital Melbourne

    Fitzroy, Victoria, Australia

  • Otto-Wagner-Spital Baumgartner Hohe

    Vienna, Austria

  • Universitatsklinium St. Polten

    Sankt Pölten, Lower Austria, Austria

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

  • Odense University Hospital

    Odense C, Denmark

  • Hopital Albert Michallon

    Grenoble, Auvergne-Rhône-Alpes, France

  • Centre Leon Berard

    Lyon, Auvergne-Rhône-Alpes, France

  • Centre de Lutte Contre le Cancer Francois Baclesse

    Caen, Basse-normandie, France

  • Hopital Charles Nicolle

    Rouen, Haute-normandie, France

  • Centre Hospitalier Intercommunal de Creteil

    Créteil, Île-de-France Region, France

  • Hopital Tenon

    Paris, Île-de-France Region, France

  • Centre Hospitalier Universitaire Hopital Nord

    Marseille, Provence-Alpes-Côte d'Azur Region, France

  • Evangelische Lungenklinik Berlin

    Berlin, Germany

  • Studiengesellschaft Haemato-Onkologie Hamburg Prof. Laack und Partner

    Hamburg, Germany

  • Universitatsklinik Freiburg

    Freiburg im Breisgau, Baden-Wurttemberg, Germany

  • Thoraxklinik Heidelberg gGmbH

    Heidelberg, Baden-Wurttemberg, Germany

  • Pius Hospital Oldenburg

    Oldenburg, Lower Saxony, Germany

  • Kliniken der Stadt Koeln gGmbH - Krankenhaus Merheim

    Cologne, North Rhine-Westphalia, Germany

  • Queen Mary Hospital

    Hong Kong, Hong Kong

  • Queen Elizabeth Hospital

    Kowloon, Hong Kong

  • Tuen Mun Hospital

    Tuenmen, New Territories, Hong Kong

  • Azienda Ospedaliera San Giuseppe Moscati

    Avellino, Italy

  • Istituto Oncologico di Bari Giovanni Paolo II

    Bari, Italy

  • Azienda Ospedaliero Universitaria di Bologna Policlinico Sant'Orsola-Malpighi

    Bologna, Italy

  • Istituto Scientifico Universitario San Raffaele

    Milan, Italy

Showing 40 of 91 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.